10116102Targeted Nanoparticle Hydrogel Therapies for Ovarian CancerClosedCollaborative R&DInnovate UKSferola Ltd is developing a next-generation nanoparticle hydrogel for epithelial ovarian cancer, capable of delivering targeted therapeutic nanoparticles to tumour tissues and testing it in-vitro and in-vivo. Ovarian tumours represent a significant public health burden, yet our ability to treat this type of cancer is lacking due to vague symptoms resulting in late stage diagnostics, aggressive nature of the tumour, its location, limited response to current chemotherapy and high recurrence rate resulting in 10 year median survival rate of 35%.